JP2003300959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003300959A5 JP2003300959A5 JP2003021750A JP2003021750A JP2003300959A5 JP 2003300959 A5 JP2003300959 A5 JP 2003300959A5 JP 2003021750 A JP2003021750 A JP 2003021750A JP 2003021750 A JP2003021750 A JP 2003021750A JP 2003300959 A5 JP2003300959 A5 JP 2003300959A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- atom
- dihydro
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 biphenylyl group Chemical group 0.000 claims 406
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 126
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 125
- 229910052757 nitrogen Inorganic materials 0.000 claims 114
- 125000000217 alkyl group Chemical group 0.000 claims 91
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 73
- 150000001875 compounds Chemical class 0.000 claims 69
- 229910052799 carbon Inorganic materials 0.000 claims 59
- 125000003277 amino group Chemical group 0.000 claims 58
- 125000004076 pyridyl group Chemical group 0.000 claims 57
- 150000001721 carbon Chemical group 0.000 claims 54
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 48
- 229910052801 chlorine Inorganic materials 0.000 claims 45
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 44
- 229910052731 fluorine Inorganic materials 0.000 claims 44
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 43
- 125000004432 carbon atom Chemical group C* 0.000 claims 41
- 125000001153 fluoro group Chemical group F* 0.000 claims 41
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 41
- 125000001424 substituent group Chemical group 0.000 claims 39
- 125000001309 chloro group Chemical group Cl* 0.000 claims 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 32
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 31
- 125000004663 dialkyl amino group Chemical group 0.000 claims 31
- 125000000623 heterocyclic group Chemical group 0.000 claims 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 31
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 30
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000006239 protecting group Chemical group 0.000 claims 30
- 125000003545 alkoxy group Chemical group 0.000 claims 28
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 27
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 25
- 125000002252 acyl group Chemical group 0.000 claims 25
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 claims 25
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 24
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 24
- 125000003282 alkyl amino group Chemical class 0.000 claims 24
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 24
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 23
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 21
- 239000001301 oxygen Substances 0.000 claims 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 20
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims 18
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 16
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 16
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 15
- 125000001624 naphthyl group Chemical group 0.000 claims 14
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 12
- 125000004434 sulfur atom Chemical group 0.000 claims 12
- 238000006243 chemical reaction Methods 0.000 claims 11
- 125000002541 furyl group Chemical group 0.000 claims 11
- 125000002883 imidazolyl group Chemical group 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 11
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 11
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims 10
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 10
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 10
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 10
- 239000002243 precursor Substances 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 10
- 239000011593 sulfur Substances 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 9
- 125000003884 phenylalkyl group Chemical group 0.000 claims 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims 9
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 9
- 125000000335 thiazolyl group Chemical group 0.000 claims 9
- 125000006546 (C4-C10) cycloalkyl group Chemical group 0.000 claims 8
- 125000001589 carboacyl group Chemical group 0.000 claims 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 8
- 125000000524 functional group Chemical group 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 7
- 125000002723 alicyclic group Chemical group 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 6
- 125000005605 benzo group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 239000000460 chlorine Chemical group 0.000 claims 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 5
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 4
- 150000001735 carboxylic acids Chemical class 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 3
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical group CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical group CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 2
- 239000012948 isocyanate Substances 0.000 claims 2
- 150000002513 isocyanates Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical group C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 claims 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 150000003335 secondary amines Chemical class 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19636623A DE19636623A1 (de) | 1996-09-10 | 1996-09-10 | Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19636623.2 | 1996-09-10 | ||
| DE19720011A DE19720011A1 (de) | 1997-05-14 | 1997-05-14 | Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Hetstellung |
| DE19720011.7 | 1997-05-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51322798A Division JP3483893B2 (ja) | 1996-09-10 | 1997-09-08 | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003300959A JP2003300959A (ja) | 2003-10-21 |
| JP2003300959A5 true JP2003300959A5 (enExample) | 2005-06-16 |
Family
ID=26029200
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51322798A Expired - Fee Related JP3483893B2 (ja) | 1996-09-10 | 1997-09-08 | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
| JP2003021750A Pending JP2003300959A (ja) | 1996-09-10 | 2003-01-30 | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51322798A Expired - Fee Related JP3483893B2 (ja) | 1996-09-10 | 1997-09-08 | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6344449B1 (enExample) |
| EP (2) | EP0927192B1 (enExample) |
| JP (2) | JP3483893B2 (enExample) |
| CN (1) | CN1129605C (enExample) |
| AR (1) | AR009742A1 (enExample) |
| AT (2) | ATE266673T1 (enExample) |
| AU (1) | AU721035C (enExample) |
| BG (1) | BG64214B1 (enExample) |
| BR (1) | BR9712023A (enExample) |
| CA (1) | CA2262818A1 (enExample) |
| CO (1) | CO4910127A1 (enExample) |
| CZ (1) | CZ82399A3 (enExample) |
| DE (2) | DE59711622D1 (enExample) |
| DK (1) | DK0927192T3 (enExample) |
| EA (1) | EA004037B1 (enExample) |
| EE (1) | EE04375B1 (enExample) |
| ES (2) | ES2314305T3 (enExample) |
| HR (1) | HRP970481B1 (enExample) |
| ID (1) | ID21045A (enExample) |
| IL (1) | IL128118A0 (enExample) |
| MY (1) | MY140677A (enExample) |
| NO (1) | NO991130L (enExample) |
| NZ (1) | NZ334543A (enExample) |
| PE (1) | PE109698A1 (enExample) |
| PT (1) | PT927192E (enExample) |
| RS (1) | RS49791B (enExample) |
| SA (1) | SA97180668B1 (enExample) |
| SK (1) | SK285631B6 (enExample) |
| TR (1) | TR199900537T2 (enExample) |
| TW (2) | TW498076B (enExample) |
| UY (1) | UY24704A1 (enExample) |
| WO (1) | WO1998011128A1 (enExample) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025372A (en) * | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
| JP2002525371A (ja) * | 1998-09-30 | 2002-08-13 | メルク シャープ エンド ドーム リミテッド | Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン |
| GB9821898D0 (en) | 1998-10-08 | 1998-12-02 | Pfizer Ltd | Heterocycles |
| US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
| DE19911039A1 (de) * | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6387932B1 (en) | 1999-06-25 | 2002-05-14 | Merck & Co., Inc. | Somatostatin agonists |
| US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
| DE19937304C2 (de) * | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
| DE19952147A1 (de) | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CZ20021492A3 (cs) | 1999-11-04 | 2003-06-18 | Ortho-Mcneil Pharmaceutical, Inc. | Nepeptidové substituované benzothiazepiny jako antagonisté vazopresinu |
| DE19963868A1 (de) * | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CA2397981C (en) | 2000-03-06 | 2010-12-21 | Acadia Pharmaceuticals, Inc. | Azacyclic compounds for use in the treatment of serotonin related diseases |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| ES2421948T3 (es) * | 2001-03-01 | 2013-09-06 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos |
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| ES2323876T3 (es) * | 2001-04-18 | 2009-07-27 | Euro-Celtique S.A. | Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor. |
| MXPA03011722A (es) | 2001-07-02 | 2004-03-19 | Aztrazeneca Ab | Derivados de piperidina utiles como moduladores de actividad de quimiocina. |
| US6977264B2 (en) * | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7115607B2 (en) * | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US20030181462A1 (en) * | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
| DE10139410A1 (de) * | 2001-08-17 | 2003-02-27 | Boehringer Ingelheim Pharma | Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| ATE466014T1 (de) | 2001-12-28 | 2010-05-15 | Acadia Pharm Inc | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren |
| DE10206770A1 (de) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
| US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
| US20040014679A1 (en) * | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
| US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| CN100558728C (zh) | 2002-06-05 | 2009-11-11 | 布里斯托尔-迈尔斯斯奎布公司 | 降钙素基因相关肽受体拮抗剂 |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| DE10227294A1 (de) * | 2002-06-19 | 2004-01-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung |
| US20040076587A1 (en) * | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| MXPA04012893A (es) | 2002-06-24 | 2005-03-31 | Acadia Pharm Inc | Derivados de piperidina n-substituidos como agentes receptores de serotonina. |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| GB0218326D0 (en) * | 2002-08-07 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| WO2004024720A1 (en) * | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7595312B2 (en) * | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
| DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7601740B2 (en) | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| US20050042179A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine |
| US20050042180A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder |
| US20050042178A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder |
| US20050043247A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative |
| US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| CA2545644C (en) * | 2003-11-12 | 2011-11-01 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
| US7855207B2 (en) | 2003-11-20 | 2010-12-21 | Janssen Pharmaceutica, Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors |
| SG150534A1 (en) * | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors |
| US7569578B2 (en) * | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| UA89618C2 (ru) * | 2003-12-05 | 2010-02-25 | Янссен Фармацевтика Н.В. | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы |
| JP2007524568A (ja) | 2003-12-05 | 2007-08-30 | ブリストル−マイヤーズ スクイブ カンパニー | カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト |
| DE102004006893A1 (de) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin |
| US20050192230A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim International Gambh | Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine |
| DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| US7547694B2 (en) * | 2004-04-15 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| US20050282857A1 (en) * | 2004-04-15 | 2005-12-22 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004018794A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018795A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018796A1 (de) * | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050233980A1 (en) * | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| US7696195B2 (en) * | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004019492A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| WO2006003147A1 (en) * | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
| CA2569826C (en) | 2004-06-30 | 2013-07-16 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| SG154432A1 (en) | 2004-06-30 | 2009-08-28 | Janssen Pharmaceutica Nv | Quinazolinedione derivatives as parp inhibitors |
| US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| DK1794126T3 (da) | 2004-09-27 | 2013-06-24 | Acadia Pharm Inc | Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| DE102004063753A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
| DE102004063752A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| EP1770091A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| US7439237B2 (en) | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| JP2009501793A (ja) | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | 新規ピペリジン誘導体 |
| DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| DE102005042828A1 (de) * | 2005-09-09 | 2007-03-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGPR-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1770087A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1770086A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102005050892A1 (de) * | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| KR20080068062A (ko) | 2005-11-14 | 2008-07-22 | 리나트 뉴로사이언스 코퍼레이션 | 칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법 |
| WO2007061677A2 (en) * | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
| DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| WO2008079945A2 (en) * | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
| ES2381446T3 (es) | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
| ES2423485T3 (es) | 2007-03-19 | 2013-09-20 | Acadia Pharmaceuticals Inc. | Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| EP2215075B1 (en) | 2007-10-26 | 2013-12-11 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as parp inhibitors |
| BRPI0908276B8 (pt) | 2008-03-04 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite |
| ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| HRP20150139T1 (hr) | 2008-03-27 | 2015-05-22 | Janssen Pharmaceutica N.V. | Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina |
| AU2009228945B2 (en) | 2008-03-27 | 2013-05-02 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
| RU2535074C2 (ru) | 2009-08-28 | 2014-12-10 | Лэйбрис Байолоджикс, Инк. | Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| SG194973A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| US9745373B2 (en) | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
| JP5988087B2 (ja) * | 2012-06-07 | 2016-09-07 | Dic株式会社 | 化合物の製造方法 |
| US9040533B2 (en) | 2012-12-27 | 2015-05-26 | Purdue Pharma L.P. | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| ES2890492T3 (es) | 2015-07-20 | 2022-01-20 | Acadia Pharm Inc | Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| AU2020206241A1 (en) | 2019-01-08 | 2021-08-26 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| WO2022185224A1 (en) | 2021-03-02 | 2022-09-09 | Mark Hasleton | Treatment and/or reduction of occurrence of migraine |
| US20250109188A1 (en) | 2021-08-24 | 2025-04-03 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| WO2024100171A1 (en) | 2022-11-11 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Olcegepant for treating sepsis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873342A (en) * | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
| CA1320734C (en) * | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| US4873253A (en) * | 1987-03-30 | 1989-10-10 | Shosuke Okamoto | Phenylalanine derivative and proteinase inhibitor |
| AU587691B2 (en) * | 1987-03-30 | 1989-08-24 | Shosuke Okamoto | Phenylalanine derivative and proteinase inhibitor |
| US5153226A (en) * | 1989-08-31 | 1992-10-06 | Warner-Lambert Company | Acat inhibitors for treating hypocholesterolemia |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| JP2668003B2 (ja) * | 1992-06-12 | 1997-10-27 | ファイザー インク． | ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤 |
| CA2166075A1 (en) * | 1993-06-30 | 1995-01-12 | Yoshiharu Ikeda | Novel dipiperidine derivative |
| JPH10504457A (ja) * | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | カルシトニンレセプター |
| US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| FR2729855A1 (fr) * | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
-
1997
- 1997-09-08 DK DK97938928T patent/DK0927192T3/da active
- 1997-09-08 AT AT97938928T patent/ATE266673T1/de not_active IP Right Cessation
- 1997-09-08 AT AT04003959T patent/ATE402187T1/de not_active IP Right Cessation
- 1997-09-08 US US09/254,281 patent/US6344449B1/en not_active Expired - Lifetime
- 1997-09-08 AU AU41196/97A patent/AU721035C/en not_active Ceased
- 1997-09-08 SK SK297-99A patent/SK285631B6/sk unknown
- 1997-09-08 CA CA002262818A patent/CA2262818A1/en not_active Abandoned
- 1997-09-08 ES ES04003959T patent/ES2314305T3/es not_active Expired - Lifetime
- 1997-09-08 NZ NZ334543A patent/NZ334543A/en unknown
- 1997-09-08 PT PT97938928T patent/PT927192E/pt unknown
- 1997-09-08 EE EEP199900115A patent/EE04375B1/xx not_active IP Right Cessation
- 1997-09-08 TR TR1999/00537T patent/TR199900537T2/xx unknown
- 1997-09-08 JP JP51322798A patent/JP3483893B2/ja not_active Expired - Fee Related
- 1997-09-08 CN CN97197772A patent/CN1129605C/zh not_active Expired - Fee Related
- 1997-09-08 EP EP97938928A patent/EP0927192B1/de not_active Expired - Lifetime
- 1997-09-08 BR BR9712023-5A patent/BR9712023A/pt not_active Application Discontinuation
- 1997-09-08 IL IL12811897A patent/IL128118A0/xx unknown
- 1997-09-08 DE DE59711622T patent/DE59711622D1/de not_active Expired - Lifetime
- 1997-09-08 ES ES97938928T patent/ES2221691T3/es not_active Expired - Lifetime
- 1997-09-08 CZ CZ99823A patent/CZ82399A3/cs unknown
- 1997-09-08 EP EP04003959A patent/EP1440976B1/de not_active Expired - Lifetime
- 1997-09-08 WO PCT/EP1997/004862 patent/WO1998011128A1/de not_active Ceased
- 1997-09-08 ID IDW990071A patent/ID21045A/id unknown
- 1997-09-08 DE DE59712953T patent/DE59712953D1/de not_active Expired - Lifetime
- 1997-09-08 EA EA199900278A patent/EA004037B1/ru not_active IP Right Cessation
- 1997-09-09 PE PE1997000801A patent/PE109698A1/es not_active Application Discontinuation
- 1997-09-09 HR HR970481A patent/HRP970481B1/xx not_active IP Right Cessation
- 1997-09-09 RS YUP-372/97A patent/RS49791B/sr unknown
- 1997-09-09 MY MYPI97004176A patent/MY140677A/en unknown
- 1997-09-10 AR ARP970104149A patent/AR009742A1/es unknown
- 1997-09-10 TW TW089125839A patent/TW498076B/zh not_active IP Right Cessation
- 1997-09-10 TW TW086113120A patent/TW477792B/zh not_active IP Right Cessation
- 1997-09-10 CO CO97052652A patent/CO4910127A1/es unknown
- 1997-09-10 UY UY24704A patent/UY24704A1/es not_active IP Right Cessation
- 1997-12-01 SA SA97180668A patent/SA97180668B1/ar unknown
-
1999
- 1999-03-09 NO NO991130A patent/NO991130L/no not_active Application Discontinuation
- 1999-03-15 BG BG103250A patent/BG64214B1/bg unknown
-
2001
- 2001-02-21 US US09/789,391 patent/US20010036946A1/en not_active Abandoned
-
2003
- 2003-01-30 JP JP2003021750A patent/JP2003300959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003300959A5 (enExample) | ||
| RU2274639C2 (ru) | Производные замещенного триазолдиамина, фармацевтическая композиция на их основе и способ ее получения | |
| EP2811997B1 (en) | Substituted prolines/piperidines as orexin receptor antagonists | |
| EP1490367B1 (en) | Imidazopyridine derivatives as kinase inhibitors | |
| US7230001B1 (en) | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | |
| KR101404360B1 (ko) | 이미다졸 유도체 | |
| AU679045B2 (en) | Benzimidazole derivatives | |
| DK2686310T5 (en) | Benzodioxan-INHIBITORERAFLEUKOTRIEN PRODUCTION | |
| EP2822941B1 (en) | Benzodioxanes in combination with statins for inhibiting leukotriene production | |
| EP1076055B1 (en) | 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds | |
| ZA200500790B (en) | Substituted quinoline CCR5 receptor antagonists | |
| US20040192729A1 (en) | Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof | |
| US20110052562A1 (en) | Benzimidazoles and analogs as rho kinase inhibitors | |
| JP2003300959A (ja) | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 | |
| WO2001068585A1 (en) | Novel amide compounds | |
| JP2006206603A (ja) | ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン | |
| JP2023526052A (ja) | 変異体ｐ５３機能を復元させるための方法および化合物 | |
| HUP0400326A2 (hu) | Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| CZ2003884A3 (cs) | Sulfonamidové deriváty | |
| ZA200205181B (en) | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof. | |
| HUP0402235A2 (hu) | 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények | |
| CZ20021812A3 (cs) | Nové cyklopropany jako antagonisté CGRP, farmaceutické prostředky obsahující tyto sloučeniny a způsob jejich výroby | |
| EP2850068B1 (en) | N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases | |
| WO2014153529A1 (en) | Substituted benzimidazoles as nociceptin receptor modulators | |
| JP2010180234A (ja) | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |